Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer

Investigational New Drugs - Tập 8 - Trang 283-287 - 1990
Elizabeth A. Eisenhauer1, Kathleen I. Pritchard2, Daniele J. Perrault3, Shailendra Verma3, Joseph L. Pater1
1NCIC Clinical Trials Group, Kingston, Canada
2Women’s College Hospital, Toronto, Canada
3Ottawa Regional Cancer Centre, Ottawa, Canada

Tóm tắt

We have carried out a phase II study of intravenous menogaril given every four weeks in a group of patients with breast cancer who had received no prior chemotherapy for metastatic disease. Myelosuppression, nausea and vomiting and local reactions were seen frequently. Six partial responses (median duration 154 days) were seen in 24 eligible patients. We conclude menogaril is active in breast cancer and recommend that because it can be delivered in high doses orally, future trials in this disease should focus on intense oral schedule.

Tài liệu tham khảo

Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nonalamycin. Cancer Treat Rep 63: 1971–1978, 1979 McGovren JP: Activity of the anthracylic agent, 7-con-O-methylnogarol (7-OMEN) administered orally to mice bearing P388 or L1210 leukemia Cancer Treat Rep 64: 727–729, 1980 Bhuyan BK, Neil GL, Li LH, McGovern JP, Wiley PF: Chemistry and biological activity of 7-con-O-methylnogarol (7-con-OMEN), in ST Crooke and SD Reich (eds): Anthracyclines. Current Status and New Developments. Academic Press New York, 1980, pp 365–395 Dodion P, Sessa C, Joss R, Crespeigne N, Willems Y, Kitt M, Abrams J, Finet C, Brewer JE, Adams WJ, Earhart RH, Rozencweig M, Kenis Y, Cavalli F: Phase I study of intravenous menogaril administered intermittently. J Clin Oncol 4: 767–774, 1986 Long HJ, Powis G, Schutt AJ, Moertel C: Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous iv infusion. Cancer Treat Rep 71: 593–598, 1987 Sessa C, Gundersen S, ten Bokkel Huinink W, Renard J, Cavalli F: Phase II study of intravenous menogaril in patients with advanced breast cancer. J Natl Cancer Inst 80 (13): 1066–1069, 1988 Ahmann DL, Bisel HF, Eagan RT, Edmonson JH, Hahn RG: Controlled evaluation of adriamycin (NCS-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 58: 877–882, 1974 Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H: Combination chemotherapy and adriamycin in patients with advanced breast cancer. Cancer 38: 13–20, 1976 Gottlieb JA, Rivkin SE, Spigel SC, Hoogstraten B, O'Bryan RM, Delaney FC, Singha Kowinta A: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. Cancer 33: 519–526, 1974 Stewart DJ, Verma S, Maroun J: Phase I study of weekly oral menogaril. Proc Amer Soc Clin Oncol 7: 57, 1988 (Abstr) De Valeriola D, Dodion P, Piccart M, Joggi J, Peeters B, Van Berchem C, Crespeigne N, Wery F, Kenis Y: Phase I trial with oral menogaril (MEN; NSC 269148). Proc Am Assoc Cancer Res 28: 230, 1987 (Abstr)